

Big Pharma M&A and Licensing Deals, YTD Apr’25

Acquirer	Target	Deal Type	Date	Deal Size (\$M)	Key Asset	Deal Phase	Target + Modality	TA
	 SpringWorks™ THERAPEUTICS	M&A	04-28-2025	\$3,900	Ogsiveo	Marketed	γ-secretase + small molecule	Rare disease
	 TessellateBIO	In-licensing	04-23-2025	\$568	Undisclosed	Preclinical	N/A + N/A	Oncology
	 EARENDIL LABS	In-licensing	04-17-2025	\$1,845	HXN-1002, HXN-1003	Preclinical	α4β7, TL1A + bsAb	I&I
	 OHB Oak Hill Bio	Out-licensing	04-15-2025	Undisclosed	Rugonersen	Phase 1	UBE3A + ASO	Rare disease
	 CUE™ BIOPHARMA	In-licensing	04-14-2025	\$357	CUE-501	Preclinical	CD19, CMV + bsAb	I&I
	 恒瑞	In-licensing	04-07-2025	\$17	SHR7280	Phase 3	GnRH + small molecule	Women's health
	 Pharma Mar	In-licensing	04-03-2025	\$60	Zepzelca	Marketed	DNA + small molecule	Oncology
	 nurix	In-licensing	04-02-2025	\$480	Undisclosed	Discovery	STAT6 + small molecule	I&I
	 Lexicon pharmaceuticals	In-licensing	03-28-2025	\$1,000	LX9851	Preclinical	ACSL5 + small molecule	Metabolic
	 Abbisko 和睿	In-licensing	03-28-2025	\$605.5	Pimicotinib	Phase 3	CSF-1R + small molecule	Oncology
	 Puhe BioPharma 浦合医药	In-licensing	03-26-2025	Undisclosed	BAY 3713372	Phase 1	PRMT5 + small molecule	Oncology
	 恒瑞	In-licensing	03-25-2025	\$1,970	HRS-5346	Phase 2	Lp(a) + small molecule	Metabolic
	 礼来	In-licensing	03-24-2025	\$2,000	UBT251	Phase 1	GLP-1R, GCGR, GIPR + peptide	Metabolic
	 Syneron 元恩生肽	In-licensing	03-21-2025	\$3,475	Undisclosed	Preclinical	N/A + peptide	Metabolic, I&I
	 Ceren Bio	In-licensing	03-20-2025	\$1,900	DR-0201	Phase 1	CD20, N/A + bsAb	Oncology
	 ZEAL & ZEALAND PHARMA	In-licensing	03-12-2025	\$5,250	Petrelintide	Phase 2b	GLP-1 + peptide	Metabolic
	 2seventybio™	M&A	03-10-2025	~ \$286	Abecma	Marketed	BCMA + CAR-T cell therapy	Oncology
	 CHIMERIX	M&A	03-05-2025	\$935	Dordaviprone	Filed	DRD2, ClpP + small molecule	Oncology
	 gubra	In-licensing	03-03-2025	\$2,225	GUB014295	Phase 1	AMYP + Peptide	Metabolic
	 Kyorin	In-licensing	03-03-2025	\$833	KRP-M223	Preclinical	MRGPRX2 + small molecule	Dermatology, I&I
	 Magnet Biomedicine	In-licensing	02-28-2025	\$1,290	Undisclosed	Discovery	N/A + small molecule	Oncology
	 organovo®	In-licensing	02-25-2025	\$60	Omesdafexor	Phase 2/3	FXR + small molecule	I&I
	 FibroGen	In-licensing	02-20-2025	\$160	Roxadustat	Marketed	HIF-PHD + small molecule	Hematology
	 NEWLEOS	Out-licensing	02-13-2025	Undisclosed	RO7308480	Phase 1	GABAA-γ1 + small molecule	Neurology
	 xilio THERAPEUTICS®	In-licensing ⁽¹⁾	02-12-2025	\$2,152	Multiple	Preclinical	N/A + bi- & tri-specific Abs	Oncology
	 ANTHOS THERAPEUTICS	M&A	02-11-2025	\$3,075	Abelacimab	Phase 3	FXI, FXIa + mAb	Cardiovascular
	 Olix Pharmaceuticals	In-licensing	02-10-2025	~ \$630	OLX702A	Phase 1	MARC1 + siRNA	I&I
	 NEOMORPH	In-licensing	01-23-2025	\$1,640	Undisclosed	Discovery	N/A + small molecule	Oncology, I&I
	 IMMvention Therapeutics, Inc.	In-licensing	01-22-2025	Undisclosed	IMM-004	Preclinical	BACH1 + small molecule	Hematology
	 IDRx	M&A	01-13-2025	\$1,150	IDRX-42	Phase 1b	KIT + small molecule	Oncology
	 Intra-Cellular THERAPIES	M&A	01-13-2025	\$14,600	Caplyta	Marketed	5-HT2R, D2R+ small molecule	Psychiatry
	 SCORPION THERAPEUTICS	M&A	01-13-2025	\$2,500	STX-478	Phase 1/2	PI3Kα + small molecule	Oncology
	 Simcere	In-licensing	01-13-2025	\$1,055	SIM0500	Phase 1	GPRC5D, BCMA, CD3 + tsAb	Oncology
	 LEO	In-licensing	01-11-2025	\$1,750	Undisclosed	Preclinical	STAT6 + small molecule	I&I
	 Mediar Therapeutics	In-licensing	01-10-2025	\$786	MTX-463	Phase 1	WISP1 + mAb	Respiratory
	 和正医药 Healzen Therapeutics	In-licensing	01-10-2025	Undisclosed	Undisclosed	Preclinical	BTK + small molecule	Undisclosed
	 OXFORD BioTherapeutics	In-licensing	01-09-2025	Undisclosed	Undisclosed	Preclinical	N/A + ADC	Oncology
	 innovent 信达生物制药	In-licensing	01-01-2025	\$1,080	IBI3009	Phase 1	DLL3 + ADC	Oncology

(1) AbbVie and Xilio Tx entered into a collaboration and option-to-license agreement
Note: Includes only innovative assets; platform or technology-related deals are excluded
As of 4/29/2025; Source: [sleuthinsights.com](https://www.sleuthinsights.com) - an AI-powered biopharma competitive intelligence platform